Shigeaki Nonoyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shigeaki Nonoyama has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Kohsuke Imai
Department of Pediatrics National Defense Medical College Saitama Japan
3 shared publications - Hirokazu Kanegane
Department of Child Health and Development, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan
2 shared publications - Kunihiko Moriya
Department of Pediatrics, National Defense Medical College
2 shared publications - Tomohiro Morio
Laboratory of Immunology and Molecular Medicine, Advanced Research Initiative, Institute of Science Tokyo, Tokyo, Japan
2 shared publications A Kawana
Department of Internal Medicine 2, Division of Infectious Disease and Pulmonary Medicine, National Defence Medical College, Tokorozawa, Japan
1 shared publicationAdil Karim
Department of Immunopathology, Research Block-A, Postgraduate Institute of Medical Education and Research, Chandigarh, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1)
Centralized rapid genetic diagnosis of combined immunodeficiency in Japan
Purpose: Severe combined immunodeficiency (SCID) is a pediatric emergency, and rapid genetic diagnosis is necessary for proper patient management, leading to successful stem cell transplantation and gene therapy. Ataxia telangiectasia (AT) requires early diagnosis to prevent infectious diseases and early detection of cancer. We aimed to diagnose patients with SCID/AT as quickly as possible and link them to the best treatments via the primary immunodeficiency database in Japan (PIDJ) network. Methods: For 111 patients with suspected combined immunodeficiency, including SCID/AT, we analyzed T‐cell receptor excision circle (TREC) and sequenced 29 causative genes of SCID, including ATM, by ion semiconductor sequencing using multiplex polymerase chain reaction amplicons. In some cases, DNA extracted from dried blood spots was used for the analysis. Results: Approximately 70.8% of 0–1‐year‐old patients and 26.5% of the patients >2 years old with low TREC were diagnosed genetically, including ADA , ATM , IL2RG , IL7R , JAK3 , RAG1 , RAG2 , DCLRE1C , NHEJ1 , and LIG4 . However, only 6.9% of patients with normal TREC were genetically diagnosed ( STIM1 and ATM ) in our panel. In Japan, all patients had been genetically diagnosed after infection or other life‐threatening conditions, and >80% of patients are linked to appropriate treatment after diagnosis. Conclusions: Target gene sequencing, including SCID and AT genes, was useful for the diagnosis of patients with combined immunodeficiency with low TREC and to lead them to prompt treatment and better prognosis.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1)
Open AccessCentralized rapid genetic diagnosis of combined immunodeficiency in Japan
Purpose: Severe combined immunodeficiency (SCID) is a pediatric emergency, and rapid genetic diagnosis is necessary for proper patient management, leading to successful stem cell transplantation and gene therapy. Ataxia telangiectasia (AT) requires early diagnosis to prevent infectious diseases and early detection of cancer. We aimed to diagnose patients with SCID/AT as quickly as possible and link them to the best treatments via the primary immunodeficiency database in Japan (PIDJ) network. Methods: For 111 patients with suspected combined immunodeficiency, including SCID/AT, we analyzed T‐cell receptor excision circle (TREC) and sequenced 29 causative genes of SCID, including ATM, by ion semiconductor sequencing using multiplex polymerase chain reaction amplicons. In some cases, DNA extracted from dried blood spots was used for the analysis. Results: Approximately 70.8% of 0–1‐year‐old patients and 26.5% of the patients >2 years old with low TREC were diagnosed genetically, including ADA , ATM , IL2RG , IL7R , JAK3 , RAG1 , RAG2 , DCLRE1C , NHEJ1 , and LIG4 . However, only 6.9% of patients with normal TREC were genetically diagnosed ( STIM1 and ATM ) in our panel. In Japan, all patients had been genetically diagnosed after infection or other life‐threatening conditions, and >80% of patients are linked to appropriate treatment after diagnosis. Conclusions: Target gene sequencing, including SCID and AT genes, was useful for the diagnosis of patients with combined immunodeficiency with low TREC and to lead them to prompt treatment and better prognosis.
- Open Access
- 13 May 2023
- Published by Taylor & Francis in Immunological Medicine
- Vol. 46 (4) , 153-157
Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan
Activated phosphatidyl inositol 3-kinase-delta syndrome (APDS) due to gain-of-function variant in the class IA PI3K catalytic subunit p110δ (responsible gene: PIK3CD) was described in 2013. The disease is characterized by recurrent airway infections and bronchiectasis. It is associated with hyper-IgM syndrome due to the defect of immunoglobulin class switch recombination and decreased CD27-positive memory B cells. Patients also suffered from immune dysregulations, such as lymphadenopathy, autoimmune cytopenia or enteropathy. T-cell dysfunction due to increased senescence is associated with a decrease in CD4-positive T lymphocytes and CD45RA-positive naive T lymphocytes, along with increased susceptibility to Epstein-Barr virus/cytomegalovirus infections. In 2014, loss-of-function (LOF) mutation of p85α (responsible gene: PIK3R1), a regulatory subunit of p110δ, was identified as a causative gene, followed in 2016 by the identification of the LOF mutation of PTEN, which dephosphorylates PIP3, leading to the differentiation of APDS1 (PIK3CD-GOF), APDS2 (PIK3R1-LOF) and APDS-L (PTEN-LOF). Since the pathophysiology of patients with APDS varies with a wide range of severity, it is crucial that patients receive appropriate treatment and management. Our research group created a disease outline and a diagnostic flow chart and summarized clinical information such as the severity classification of APDS and treatment options.
- 13 May 2023
- Published by Taylor & Francis in Immunological Medicine
- Vol. 46 (4) , 153-157
Open AccessClinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan
Activated phosphatidyl inositol 3-kinase-delta syndrome (APDS) due to gain-of-function variant in the class IA PI3K catalytic subunit p110δ (responsible gene: PIK3CD) was described in 2013. The disease is characterized by recurrent airway infections and bronchiectasis. It is associated with hyper-IgM syndrome due to the defect of immunoglobulin class switch recombination and decreased CD27-positive memory B cells. Patients also suffered from immune dysregulations, such as lymphadenopathy, autoimmune cytopenia or enteropathy. T-cell dysfunction due to increased senescence is associated with a decrease in CD4-positive T lymphocytes and CD45RA-positive naive T lymphocytes, along with increased susceptibility to Epstein-Barr virus/cytomegalovirus infections. In 2014, loss-of-function (LOF) mutation of p85α (responsible gene: PIK3R1), a regulatory subunit of p110δ, was identified as a causative gene, followed in 2016 by the identification of the LOF mutation of PTEN, which dephosphorylates PIP3, leading to the differentiation of APDS1 (PIK3CD-GOF), APDS2 (PIK3R1-LOF) and APDS-L (PTEN-LOF). Since the pathophysiology of patients with APDS varies with a wide range of severity, it is crucial that patients receive appropriate treatment and management. Our research group created a disease outline and a diagnostic flow chart and summarized clinical information such as the severity classification of APDS and treatment options.
- 1 October 2018
- Published by Elsevier in Clinical Immunology
- Vol. 195, 59-66
Clinical and molecular features of X-linked hyper IgM syndrome – An experience from North India
- 1 October 2018
- Published by Elsevier in Clinical Immunology
- Vol. 195, 59-66
Clinical and molecular features of X-linked hyper IgM syndrome – An experience from North India
- Open Access
- 9 September 2010
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 15 (36) , 19659
Characteristics of paediatric patients with 2009 pandemic influenza A(H1N1) and severe, oxygen-requiring pneumonia in the Tokyo region, 1 September–31 October 2009
Binary file ES_Abstracts_Final_ECDC.txt matches
- 9 September 2010
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 15 (36) , 19659
Open AccessCharacteristics of paediatric patients with 2009 pandemic influenza A(H1N1) and severe, oxygen-requiring pneumonia in the Tokyo region, 1 September–31 October 2009
Binary file ES_Abstracts_Final_ECDC.txt matches
- Open Access
- 1 February 1998
- Published by Wiley in European Journal of Immunology
- Vol. 28 (2) , 589-598
Diminished expression of CD40 ligand may contribute to the defective humoral immunity in patients with MHC class II deficiency
Major histocompatibility complex (MHC) class II deficiency (bare lymphocyte syndrome, BLS) is a rare primary immunodeficiency classified as a subgroup of severe combined immunodeficiency. We studied T and B lymphocyte function by examining the CD40 ligand/CD40 system in three BLS patients from two unrelated families. CD40 ligand expression by maximally activated BLS T cells was diminished. This abnormality may represent immunological naïveté rather than a general T cell defect, since expression of activation marker CD69 and proliferative responses to PHA or anti‐CD3 were normal, and BLS T cells primed and restimulated in vitro expressed normal amounts of CD40 ligand. BLS B cells proliferated and produced IgE if stimulated with anti‐CD40 or soluble CD40 ligand and IL‐4. Activation of BLS B cells with soluble CD40 ligand and IL‐4 induced normal expression of activation markers, although MHC class II expression remained absent. Depressed antibody titers, lack of amplification and failure to undergo isotype switching in response to immunization with bacteriophage ϕ × 174 demonstrated defective T cell help. We conclude that BLS B cells are functionally normal if appropriately stimulated, and that the defective humoral immunity observed may be related to diminished expression of CD40 ligand on BLS T cells.
- 1 February 1998
- Published by Wiley in European Journal of Immunology
- Vol. 28 (2) , 589-598
Open AccessDiminished expression of CD40 ligand may contribute to the defective humoral immunity in patients with MHC class II deficiency
Major histocompatibility complex (MHC) class II deficiency (bare lymphocyte syndrome, BLS) is a rare primary immunodeficiency classified as a subgroup of severe combined immunodeficiency. We studied T and B lymphocyte function by examining the CD40 ligand/CD40 system in three BLS patients from two unrelated families. CD40 ligand expression by maximally activated BLS T cells was diminished. This abnormality may represent immunological naïveté rather than a general T cell defect, since expression of activation marker CD69 and proliferative responses to PHA or anti‐CD3 were normal, and BLS T cells primed and restimulated in vitro expressed normal amounts of CD40 ligand. BLS B cells proliferated and produced IgE if stimulated with anti‐CD40 or soluble CD40 ligand and IL‐4. Activation of BLS B cells with soluble CD40 ligand and IL‐4 induced normal expression of activation markers, although MHC class II expression remained absent. Depressed antibody titers, lack of amplification and failure to undergo isotype switching in response to immunization with bacteriophage ϕ × 174 demonstrated defective T cell help. We conclude that BLS B cells are functionally normal if appropriately stimulated, and that the defective humoral immunity observed may be related to diminished expression of CD40 ligand on BLS T cells.
- 1 September 1995
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 118 (3) , 534-540
Induction of CD40 in Promyelocytic HL60 cells Cultured with Retinoic Acid and/or Various Cytokines1
The antigentic protein CD40 on the surface of Blymphocytes plays an important role in their Proliferation, immunoglobulin class switching, and rescue from apoptosis in the germinal center through interaction with T Lymphocytes expressing CD40 liganed. The protein is also found on the cell surface of other antigen-presenting cells such as monocytes, Dendritic cells, and thymic epithelium cells, but its presence in other myloid cells has not been reported. We show here that CD 40 protein in induced in promyelocytic HL60 cells, when cultured with retinoic acid, a vitamin that converts them to granulocyte-like cells. The cultured cells also expressed CD15, a Marker for granulocytes, and cytochrome an essential component of the superoxide-generating system in Phagocytes, on their surface. No detectable amount of mRNA for CD40 was found in naive HL60 cells, where as alarge amount of the message was induced in the cells cultured with the vitamin. Although CD40 expression was enhanced when the cells were further cultured with GM-CSF or IFN-γ expression of CD14, a marker for Monocytes, was also enhanced. HL60 cells, therefore, express CD40 protein during differentiation not only toward monocytes but also toward granulocytes, at least transiently.
- 1 September 1995
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 118 (3) , 534-540
Induction of CD40 in Promyelocytic HL60 cells Cultured with Retinoic Acid and/or Various Cytokines1
The antigentic protein CD40 on the surface of Blymphocytes plays an important role in their Proliferation, immunoglobulin class switching, and rescue from apoptosis in the germinal center through interaction with T Lymphocytes expressing CD40 liganed. The protein is also found on the cell surface of other antigen-presenting cells such as monocytes, Dendritic cells, and thymic epithelium cells, but its presence in other myloid cells has not been reported. We show here that CD 40 protein in induced in promyelocytic HL60 cells, when cultured with retinoic acid, a vitamin that converts them to granulocyte-like cells. The cultured cells also expressed CD15, a Marker for granulocytes, and cytochrome an essential component of the superoxide-generating system in Phagocytes, on their surface. No detectable amount of mRNA for CD40 was found in naive HL60 cells, where as alarge amount of the message was induced in the cells cultured with the vitamin. Although CD40 expression was enhanced when the cells were further cultured with GM-CSF or IFN-γ expression of CD14, a marker for Monocytes, was also enhanced. HL60 cells, therefore, express CD40 protein during differentiation not only toward monocytes but also toward granulocytes, at least transiently.
- 1 September 1994
- Published by Elsevier in Clinical Immunology and Immunopathology
- Vol. 72 (3) , 373-379
Effect of IL-2 on Immunoglobulin Production by Anti-CD40-Activated Human B Cells: Synergistic Effect with IL-10 and Antagonistic Effect with IL-4
- 1 September 1994
- Published by Elsevier in Clinical Immunology and Immunopathology
- Vol. 72 (3) , 373-379
Effect of IL-2 on Immunoglobulin Production by Anti-CD40-Activated Human B Cells: Synergistic Effect with IL-10 and Antagonistic Effect with IL-4